Canada · Delayed Price · Currency is CAD Medexus Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
A diversified pharma portfolio is driving steady revenue and EBITDA, with GRAFAPEX poised to double revenue at high margins. Strong hospital uptake, favorable reimbursement, and robust clinical data support U.S. peak sales of $100–$175 million within 3–5 years.
-
Fiscal Q3 2026 saw net revenue of $25.3M and adjusted EBITDA of $4.5M, with GRAFAPEX driving growth and expected to be accretive to cash flows in Q4. Gross margin improved to 53.6%, and a new credit facility enhanced financial flexibility.
-
Graphopex outperformed expectations, driving strong adoption and positive feedback, with guidance for continued revenue growth and positive cash flow in fiscal Q3 2026. Portfolio performance was mixed, with generic competition impacting some products and gross margin improving year-over-year.
-
Q1 2026 saw strong early GRAFAPEX adoption, offsetting declines from portfolio maturity and generic competition, with $24.6M revenue and improved gross margin. GRAFAPEX is expected to drive future growth, supported by NTAP reimbursement and robust business development prospects.
Fiscal Year 2025
-
Shareholders reviewed financial statements for 2024 and 2025, elected seven directors, and reappointed PwC as auditor. All voting items passed, with results to be disclosed on SEDAR. No questions or comments were raised during the meeting.
-
A diversified rare disease-focused pharma is accelerating growth with the U.S. launch of GRAFAPEX, which is expected to more than double revenue and drive higher margins. The company leverages efficient M&A, a strong commercial platform, and is actively seeking late-stage assets for future expansion.
-
GRAFAPEX's U.S. launch drove strong early revenue and positive market response, with expectations for continued sequential growth and accretive contribution by fiscal Q4 2026. Fiscal 2025 saw record adjusted EBITDA and net income, while base franchises are expected to remain stable or slightly decline.
-
A diversified pharmaceutical company is leveraging its U.S. and Canadian infrastructure to drive growth, with Treosulfan (Grafapex) as a key catalyst expected to exceed $100 million in annual revenue and deliver higher margins. Ongoing business development and a strong balance sheet position the company for continued expansion.
-
Q3 2025 saw strong revenue and profit growth, driven by IXINITY and Rupall, and supported by disciplined cost management. FDA approval and upcoming U.S. launch of GRAFAPEX, plus a successful equity raise, position the company for future growth.
-
Revenue for Q2 2025 was $26.3 million, with improved adjusted EBITDA and positive net income. Preparations for a potential U.S. treosulfan launch are underway, and the FDA decision is expected by January 2025. Rupall faces gradual generic erosion, while investments in treosulfan ramp up.
-
Fiscal Q1 2025 saw positive net income and strong adjusted EBITDA despite lower revenue, driven by cost reductions and product performance. Rupall and Metoject showed growth, while IXINITY and Rasuvo faced declines. Treosulfan FDA decision and Gleolan U.S. exit are key near-term events.
Fiscal Year 2024
-
The meeting covered the ongoing FDA review and commercialization plans for Treosulfan, presented financials for 2023 and 2024, and confirmed the election of directors and auditor reappointment. All voting items passed, and no shareholder questions were raised.
-
Record annual revenue and adjusted EBITDA were achieved, despite Q4 revenue and net income declines. Treosulfan's FDA review is underway, with no significant revenue expected until fiscal 2026. Cost controls, product demand shifts, and leadership changes position the company for future growth.